Survival of chemo-na ïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404

ConclusionsProlonged follow-up revealed that combination therapy with afatinib and bevacizumab might improve survival outcomes inEGFR-mutant advanced non-small-cell lung cancer patients and seems to be promising.Trial registrationUMIN000015944.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research